Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alefacept Extension Study in Chronic Plaque Psoriasis
NCT00692172Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Dec 2001
- Primary completion
- Nov 2004
- Modality
- Fc-Fusion Proteins
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of alefacept in psoriasis, sponsored by Astellas Pharma. Primary endpoint: Assessment of safety including evaluation of incidence of adverse events, physical exams and laboratory monitoring. Started Dec 2001; status: completed.
02
Drugs
alefacept
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT00692172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00692172.